# Eli Lilly and Company

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/eli-lilly-and-company/

## Facts

| Field | Value |
| --- | --- |
| Country | US |
| Description | American pharmaceutical company |
| OpenAlex ID | https://openalex.org/F4320307758 |
| ROR ID | https://ror.org/01qat3289 |
| Works | 67,469 |

## Funder papers

Showing 15 of 86.

- [Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes](https://scholariq.org/papers/intensive-blood-glucose-control-and-vascular-outcomes-in-patients-with-type-2/)
- [Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes](https://scholariq.org/papers/glucose-control-and-vascular-complications-in-veterans-with-type-2-diabetes/)
- [Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-in-heart-failure-with-preserved-ejection/)
- [Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/niraparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity](https://scholariq.org/papers/effect-of-continued-weekly-subcutaneous-semaglutide-vs-placebo-on-weight-loss/)
- [Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity](https://scholariq.org/papers/tirzepatide-for-heart-failure-with-preserved-ejection-fraction-and-obesity/)
- [Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial](https://scholariq.org/papers/dulaglutide-versus-insulin-glargine-in-patients-with-type-2-diabetes-and/)
- [Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial](https://scholariq.org/papers/safety-and-tolerability-of-the-novel-non-steroidal-mineralocorticoid-receptor/)
- [<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes](https://scholariq.org/papers/i-egfr-i-mutant-adenocarcinomas-that-transform-to-small-cell-lung-cancer-and/)
- [A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease](https://scholariq.org/papers/a-randomized-controlled-study-of-finerenone-vs-eplerenone-in-patients-with/)
- [Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction](https://scholariq.org/papers/efficacy-of-dapagliflozin-on-renal-function-and-outcomes-in-patients-with-heart/)
- [Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups](https://scholariq.org/papers/canagliflozin-and-cardiovascular-and-renal-outcomes-in-type-2-diabetes-mellitus/)
- [Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial](https://scholariq.org/papers/effects-of-tirzepatide-versus-insulin-glargine-on-kidney-outcomes-in-type-2/)
- [Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial](https://scholariq.org/papers/long-term-kidney-outcomes-of-semaglutide-in-obesity-and-cardiovascular-disease/)
- [Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study](https://scholariq.org/papers/effect-of-intensive-diabetes-treatment-on-albuminuria-in-type-1-diabetes-long/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.